Pentagon swiftly halts the use of vaccine variant required to immunize deployed troops

The US Military and Defense Agency has stated that it has swiftly halted the administration of Johnson & Johnson's COVID-19 vaccine after federal health officials announced that people who have received the vaccine experienced a rare and severe blood clot. The US government's decision could deal a blow to the military's efforts to vaccinate its troops present in remote locations and overseas, predominantly dependent on the increasing availability of the Johnson & Johnson vaccine.

But Johnson & Johnson hasn't commented about this issue. The company has stated that it will allocate 86 percent fewer doses across the United States after further testing. The distribution of the single-shot vaccine has dipped down below 400,000. Federal administrators have stated that they will vaccine doses nationwide based on each state's adult population.

The Slowdown in vaccine distribution rate came in due to federal officials halting the administration of vaccines to its armed forces and deployed troops. To overcome this shortage of vaccines, the US government is planning to produce alternative vaccines. The government is planning to administrate single-dose vaccine or two-dose series made by Pfizer-BioNTech and Moderna.